THE WOODLANDS, Texas, June 21 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated announced today that Barry Mills, J.D., Ph.D. has been elected to its Board of Directors.
Dr. Mills has been the president of Bowdoin College in Brunswick, Maine since 2001. He previously spent more than 20 years as an attorney with Debevoise & Plimpton LLP in New York, where he focused on corporate law, real estate and corporate finance and served as the firm’s deputy presiding partner. He currently serves on the board of directors of Maine Bank & Trust Co., a Maine bank subsidiary of Chittenden Bank, and Galileo Fund Management Limited, as well as several philanthropic boards. Dr. Mills earned an A.B. in biochemistry and government from Bowdoin College, a Ph.D. in biology from Syracuse University and a J.D. from the Columbia University School of Law.
“With the election of Dr. Mills to Lexicon’s board of directors, we add considerable independent governance, financial and legal expertise,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. “Lexicon will benefit from Dr. Mills’ experience and insight as we continue our advancement to drug development and commercialization.”
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs addressing these targets. For targets that the company believes have high pharmaceutical value, it engages in programs for the discovery and development of small molecule, antibody and protein drugs. Lexicon has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through collaborations and strategic alliances to accelerate the development and commercialization of its discoveries.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements about Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Factors Affecting Forward-Looking Statements” and “Business - Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Lexicon Genetics Incorporated
CONTACT: Bobbie Faulkner, Manager, Investor Relations of Lexicon GeneticsIncorporated, +1-281-863-3503, or bfaulkner@lexgen.com
Web site: http://www.lexicon-genetics.com/
